Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | CA12 | O43570 | 6/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 6/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20158449 | 0.95 | CA12 (0.37) | CA2CA12CA14APLNRTDP1 | |
| SCHEMBL5494091 | 0.88 | APLNR (0.40) | CA2CA12CA14APLNRTDP1 | |
| SCHEMBL20158289 | 0.85 | APLNR (0.37) | CA2CA12CA14APLNRTDP1 | |
| SCHEMBL18906911 | 0.85 | APLNR (0.37) | CA2CA12CA14APLNRTDP1 | |
| SCHEMBL18906915 | 0.85 | APLNR (0.37) | CA2CA12CA14APLNRTDP1 | |
| SCHEMBL22515382 | 0.85 | CA2 (0.36) | CA2CA12CA14APLNRTDP1 | |
| SCHEMBL21694996 | 0.84 | APLNR (0.40) | CA2CA12CA14APLNRTDP1 | |
| SCHEMBL22339730 | 0.83 | ADORA1 (0.37) | CA2CA12CA14APLNRTDP1 | |
| SCHEMBL22030517 | 0.83 | CA12 (0.46) | CA2CA12CA14APLNRTDP1 | |
| SCHEMBL25143061 | 0.81 | APLNR (0.36) | CA2CA12CA14APLNRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135306-B2 | Antibody-drug conjugates | CHO Pharma Inc. (TW) | 2021-10-05 | — | — | US | disclosed |
| US-20190328895-A1 | ANTIBODY-DRUG CONJUGATES | CHO Pharma Inc. (TW) | 2019-10-31 | — | — | US | disclosed |
| US-20180133340-A1 | ANTIBODY-DRUG CONJUGATES | CHO Pharma Inc. (TW) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328895-A1 | ANTIBODY-DRUG CONJUGATES | CSGALNACT1, ADCY1, NEU1 | CA2 510/4885CA12 59/4885CA14 147/4885 |
| US-20180133340-A1 | ANTIBODY-DRUG CONJUGATES | CSGALNACT1, ST6GAL1, PA2G4 | CA2 552/4885CA12 97/4885CA14 216/4885 |
| US-11135306-B2 | Antibody-drug conjugates | CSGALNACT1, ST6GAL1, PA2G4 | CA2 552/4885CA12 97/4885CA14 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.